TY - JOUR
T1 - Implanted cannula-mediated repetitive administration of Aβ25-35 into the mouse cerebral ventricle effectively impairs spatial working memory
AU - Yamada, Marina
AU - Chiba, Tomohiro
AU - Sasabe, Jumpei
AU - Nawa, Mikiro
AU - Tajima, Hirohisa
AU - Niikura, Takako
AU - Terashita, Kenzo
AU - Aiso, Sadakazu
AU - Kita, Yoshiko
AU - Matsuoka, Masaaki
AU - Nishimoto, Ikuo
N1 - Funding Information:
This work was supported in part by a grant from Keio University Grant-in-Aid for Encouragement of Young Medical Scientist (M.Y. and M.N.); The Mochida Memorial Foundation for Medical and Pharmaceutical Research (T.N.) and Japan Society for the Promotion of Sciences.
PY - 2005/11/7
Y1 - 2005/11/7
N2 - Amyloid β (Aβ) is closely related to the onset of Alzheimer's disease (AD). To construct AD animal models, a bolus administration of a large dose of toxic Aβ into the cerebral ventricles of rodents has been performed in earlier studies. In parallel, a continuous infusion system via an osmotic pump into the cerebral ventricle has been developed to make a rat AD model. In this study, we developed a mouse AD model by repetitive administration of Aβ25-35 via a cannula implanted into the cerebral ventricle. Using this administration system, we reproducibly constructed a mouse with impaired spatial working memory. In accordance with the occurrence of the abnormal mouse behavior, we found that the number of choline acetyltransferase (ChAT)-positive neurons was reduced in paraventricular regions of brains of Aβ25-35- administered mice in a dose-dependent manner. Considering that the repetitive administration of a small dose of toxic Aβ via an implanted cannula leads to a brain status more resembling that of the AD patients than a bolus injection of a large dose of Aβ, and therapeutic as well as toxic agents are able to be repeatedly and reliably administered via an implanted cannula, we concluded that the implanted cannula-bearing AD mouse model is useful for development of new AD therapy.
AB - Amyloid β (Aβ) is closely related to the onset of Alzheimer's disease (AD). To construct AD animal models, a bolus administration of a large dose of toxic Aβ into the cerebral ventricles of rodents has been performed in earlier studies. In parallel, a continuous infusion system via an osmotic pump into the cerebral ventricle has been developed to make a rat AD model. In this study, we developed a mouse AD model by repetitive administration of Aβ25-35 via a cannula implanted into the cerebral ventricle. Using this administration system, we reproducibly constructed a mouse with impaired spatial working memory. In accordance with the occurrence of the abnormal mouse behavior, we found that the number of choline acetyltransferase (ChAT)-positive neurons was reduced in paraventricular regions of brains of Aβ25-35- administered mice in a dose-dependent manner. Considering that the repetitive administration of a small dose of toxic Aβ via an implanted cannula leads to a brain status more resembling that of the AD patients than a bolus injection of a large dose of Aβ, and therapeutic as well as toxic agents are able to be repeatedly and reliably administered via an implanted cannula, we concluded that the implanted cannula-bearing AD mouse model is useful for development of new AD therapy.
KW - Alzheimer's disease
KW - Amyloid beta (Aβ)
KW - Implanted cannula
KW - Spontaneous alternation behavior
KW - Y-maze test
UR - http://www.scopus.com/inward/record.url?scp=25144516321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=25144516321&partnerID=8YFLogxK
U2 - 10.1016/j.bbr.2005.03.026
DO - 10.1016/j.bbr.2005.03.026
M3 - Article
C2 - 16122819
AN - SCOPUS:25144516321
SN - 0166-4328
VL - 164
SP - 139
EP - 146
JO - Behavioural Brain Research
JF - Behavioural Brain Research
IS - 2
ER -